Kenneth J Widder Net Worth

The estimated Net Worth of Kenneth J Widder is at least $169 ezer dollars as of 19 July 2024. Kenneth Widder owns over 3,333 units of Personalis Inc stock worth over $169,408 and over the last 11 years Kenneth sold PSNL stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kenneth Widder PSNL stock SEC Form 4 insiders trading

Kenneth has made over 14 trades of the Personalis Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Kenneth exercised 3,333 units of PSNL stock worth $93,024 on 19 July 2024.

The largest trade Kenneth's ever made was buying 450,000 units of Personalis Inc stock on 22 February 2017 worth over $1,305,000. On average, Kenneth trades about 10,718 units every 76 days since 2013. As of 19 July 2024 Kenneth still owns at least 28,472 units of Personalis Inc stock.

You can see the complete history of Kenneth Widder stock trades at the bottom of the page.

Insiders trading at Personalis Inc

Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci és Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.

What does Personalis Inc do?

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.

Complete history of Kenneth Widder stock trades at Evoke Pharma Inc, QuidelOrtho és Personalis Inc

Personalis Inc executives and stock owners

Personalis Inc executives and other stock owners filed with the SEC include:

• Aaron Tachibana,
  Chief Financial Officer
• Clinton Musil,
  Chief Business Officer
• John Stephen West,
  Co-Founder, CEO, Pres & Director
• Paul Ricci,
  Independent Director
• John West,
  President, Chief Executive Officer, Director
• Dr. Richard Chen M.D., M.S., MS,
  Sr. VP of R&D and Chief Medical Officer
• Richard Chen,
  Chief Science Officer
• Aaron L. Tachibana,
  Sr. VP & CFO
• Dr. Richard Chen M.S., M.D., MS,
  Chief Scientific Officer
• A. Blaine Bowman,
  Independent Director
• Alan Colowick,
  Independent Director
• Karin Eastham,
  Independent Director
• Jonathan MacQuitty,
  Independent Chairman of the Board
• Kenneth Ludlum,
  Independent Director
• Patrick Balthrop,
  Independent Director
• Stephen Moore,
  General Counsel
• Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Michael J. Fitzpatrick,
  VP of Worldwide Sales
• Stephen M. Moore J.D.,
  VP, Gen. Counsel & Corp. Sec.
• Carol J. Tillis,
  VP of Fin. & Admin.
• Dr. Michael Snyder Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Atul Butte,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Kenneth J Widder,
  
• Olivia Kyusuk Bloom,
  
• Ken Ludlum,
  Director
• Mdv Partners, L.L.C.Mdv Ix ...,
  
• Venture Partners Viii Lp Li...,
  
• Venture Partners Select Iv,...,
  
• Llp Abingworth,
  
• Christopher M Hall,
  PRESIDENT AND CEO
• Venture Partners Select Iv,...,
  
• Ai, Inc. Tempus,
  10% owner
• Lonnie Shoff,